Skip to main content
OTCMKTS:LXRP

Lexaria Bioscience Competitors

Add
Compare
Today's Range N/A
50-Day Range
$0.22
$0.28
52-Week Range N/A
Volume2.15 million shs
Average Volume608,350 shs
Market Capitalization$22.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Lexaria Bioscience (OTCMKTS:LXRP) Vs. MPVDF, QTMM, USAU, AAU, RYSMF, and OPNT

Should you be buying LXRP stock or one of its competitors? Companies in the industry of "metal mining" are considered alternatives and competitors to Lexaria Bioscience, including Mountain Province Diamonds (MPVDF), Quantum Materials (QTMM), U.S. Gold (USAU), Almaden Minerals (AAU), Royal Standard Minerals (RYSMF), and Opiant Pharmaceuticals (OPNT).

Mountain Province Diamonds (OTCMKTS:MPVDF) and Lexaria Bioscience (OTCMKTS:LXRP) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Mountain Province Diamonds and Lexaria Bioscience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mountain Province Diamonds10001.00
Lexaria Bioscience0000N/A

Mountain Province Diamonds currently has a consensus target price of $0.05, indicating a potential downside of 87.91%.

Valuation & Earnings

This table compares Mountain Province Diamonds and Lexaria Bioscience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mountain Province Diamonds$208.24 million0.42$-97,030,000.00N/AN/A
Lexaria Bioscience$380,000.000.00$-4,090,000.00N/AN/A

Lexaria Bioscience has lower revenue, but higher earnings than Mountain Province Diamonds.

Institutional & Insider Ownership

0.1% of Lexaria Bioscience shares are held by institutional investors. 4.8% of Mountain Province Diamonds shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Mountain Province Diamonds and Lexaria Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mountain Province Diamonds-90.08%-20.73%-7.41%
Lexaria Bioscience-1,046.77%-157.62%-148.09%

Summary

Mountain Province Diamonds beats Lexaria Bioscience on 5 of the 7 factors compared between the two stocks.

Lexaria Bioscience (OTCMKTS:LXRP) and Quantum Materials (OTCMKTS:QTMM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Lexaria Bioscience and Quantum Materials, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Quantum Materials0000N/A

Valuation and Earnings

This table compares Lexaria Bioscience and Quantum Materials' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.000.00$-4,090,000.00N/AN/A
Quantum Materials$20,000.003,822.50$-9,400,000.00N/AN/A

Lexaria Bioscience has higher revenue and earnings than Quantum Materials.

Insider and Institutional Ownership

0.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 0.0% of Quantum Materials shares are held by institutional investors. 12.8% of Quantum Materials shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Lexaria Bioscience and Quantum Materials' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Quantum MaterialsN/AN/AN/A

Summary

Quantum Materials beats Lexaria Bioscience on 4 of the 7 factors compared between the two stocks.

Lexaria Bioscience (OTCMKTS:LXRP) and U.S. Gold (NASDAQ:USAU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Lexaria Bioscience and U.S. Gold, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
U.S. Gold00203.00

U.S. Gold has a consensus price target of $18.00, indicating a potential upside of 68.86%.

Valuation and Earnings

This table compares Lexaria Bioscience and U.S. Gold's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.000.00$-4,090,000.00N/AN/A
U.S. GoldN/AN/A$-5,250,000.00($3.17)-3.36

Lexaria Bioscience has higher revenue and earnings than U.S. Gold.

Insider and Institutional Ownership

0.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 2.4% of U.S. Gold shares are held by institutional investors. 9.9% of U.S. Gold shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Lexaria Bioscience and U.S. Gold's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
U.S. GoldN/A-60.15%-57.57%

Summary

U.S. Gold beats Lexaria Bioscience on 6 of the 8 factors compared between the two stocks.

Lexaria Bioscience (OTCMKTS:LXRP) and Almaden Minerals (NYSEAMERICAN:AAU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Lexaria Bioscience and Almaden Minerals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Almaden Minerals00103.00

Almaden Minerals has a consensus price target of $1.10, indicating a potential upside of 115.69%.

Valuation and Earnings

This table compares Lexaria Bioscience and Almaden Minerals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.000.00$-4,090,000.00N/AN/A
Almaden MineralsN/AN/A$-2,840,000.00N/AN/A

Almaden Minerals has lower revenue, but higher earnings than Lexaria Bioscience.

Insider and Institutional Ownership

0.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 4.9% of Almaden Minerals shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Lexaria Bioscience and Almaden Minerals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Almaden MineralsN/A-4.57%-4.24%

Summary

Almaden Minerals beats Lexaria Bioscience on 6 of the 7 factors compared between the two stocks.

Lexaria Bioscience (OTCMKTS:LXRP) and Royal Standard Minerals (OTCMKTS:RYSMF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

0.1% of Lexaria Bioscience shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Lexaria Bioscience and Royal Standard Minerals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.000.00$-4,090,000.00N/AN/A
Royal Standard MineralsN/AN/A$-20,000.00N/AN/A

Royal Standard Minerals has lower revenue, but higher earnings than Lexaria Bioscience.

Analyst Ratings

This is a summary of recent recommendations and price targets for Lexaria Bioscience and Royal Standard Minerals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Royal Standard Minerals0000N/A

Profitability

This table compares Lexaria Bioscience and Royal Standard Minerals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Royal Standard MineralsN/AN/A-109.46%

Summary

Royal Standard Minerals beats Lexaria Bioscience on 4 of the 6 factors compared between the two stocks.

Lexaria Bioscience (OTCMKTS:LXRP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

0.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 20.8% of Opiant Pharmaceuticals shares are held by institutional investors. 28.0% of Opiant Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lexaria Bioscience and Opiant Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.000.00$-4,090,000.00N/AN/A
Opiant Pharmaceuticals$40.52 million1.30$11.59 million$0.2060.75

Opiant Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience.

Analyst Recommendations

This is a summary of recent ratings and price targets for Lexaria Bioscience and Opiant Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Opiant Pharmaceuticals0000N/A

Profitability

This table compares Lexaria Bioscience and Opiant Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Opiant Pharmaceuticals-0.39%-0.31%-0.27%

Summary

Opiant Pharmaceuticals beats Lexaria Bioscience on 7 of the 7 factors compared between the two stocks.


Lexaria Bioscience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MPVDF
Mountain Province Diamonds
0.5$0.41flat$80.96 million$208.24 million-0.62Analyst Report
News Coverage
Quantum Materials logo
QTMM
Quantum Materials
0.5$0.11flat$76.45 million$20,000.000.00
U.S. Gold logo
USAU
U.S. Gold
1.4$10.66flat$75.25 millionN/A-3.36News Coverage
AAU
Almaden Minerals
1.1$0.51flat$69.98 millionN/A-17.00
RYSMF
Royal Standard Minerals
0.5$0.07flat$61.42 millionN/A-6.67
Opiant Pharmaceuticals logo
OPNT
Opiant Pharmaceuticals
0.5$12.15flat$52.62 million$40.52 million-121.48Earnings Announcement
News Coverage
Gap Up
Avalon Advanced Materials logo
AVLNF
Avalon Advanced Materials
0.7$0.13flat$47.73 million$100,000.000.00Gap Down
Wealth Minerals logo
WMLLF
Wealth Minerals
0.5$0.27flat$47.45 millionN/A-6.82Gap Up
Paramount Gold Nevada logo
PZG
Paramount Gold Nevada
1.7$1.04flat$39.20 million$730,000.000.00News Coverage
Bunker Hill Mining logo
BHLL
Bunker Hill Mining
0.5$0.22flat$33.62 millionN/A-0.54Upcoming Earnings
Gap Up
LEXX
Lexaria Bioscience
0.0$6.19flat$31.59 million$380,000.000.00Gap Up
Pure Energy Minerals logo
PEMIF
Pure Energy Minerals
0.5$0.96flat$31.00 millionN/A0.00News Coverage
Gap Down
ATLRF
Atlatsa Resources
0.5$0.05flat$29.99 million$4.26 million0.00High Trading Volume
Gap Up
Quaterra Resources logo
QTRRF
Quaterra Resources
0.6$0.13flat$29.97 millionN/A0.00News Coverage
Gap Up
Silver Bull Resources logo
SVBL
Silver Bull Resources
0.5$0.83flat$28.07 millionN/A-10.41
PBMLF
Pacific Booker Minerals
0.5$1.65flat$27.67 millionN/A-55.00News Coverage
SFEG
Santa Fe Gold
0.6$0.06flat$25.73 millionN/A0.00News Coverage
Gap Up
AMLM
American Lithium Minerals
1.0$0.28flat$19.52 millionN/A0.00Gap Up
Lomiko Metals logo
LMRMF
Lomiko Metals
0.4$0.10flat$17.71 millionN/A-5.10Gap Down
New Age Metals logo
NMTLF
New Age Metals
0.0$0.13flat$17.32 millionN/A0.00News Coverage
Gap Up
VSMR
Verify Smart
0.0$0.13flat$15.02 millionN/A0.00Gap Down
Alderon Iron Ore logo
AXXDF
Alderon Iron Ore
0.5$0.09flat$12.13 millionN/A0.00
Thunder Mountain Gold logo
THMG
Thunder Mountain Gold
0.7$0.16flat$9.50 million$1.95 million5.27Upcoming Earnings
Gap Down
Pelangio Exploration logo
PGXPF
Pelangio Exploration
0.5$0.12flat$8.48 millionN/A-3.03
CPTRF
Captor Capital
0.1$0.17flat$6.69 million$9.39 million-0.38Gap Up
Cerro Grande Mining logo
CEGMF
Cerro Grande Mining
0.5$0.01flat$5.56 millionN/A0.00
CNYCF
Searchlight Resources
0.0$0.06flat$5.33 millionN/A-3.23Gap Up
RCCMF
Nippon Dragon Resources
0.0$0.03flat$5.24 millionN/A0.00
HREEF
Stans Energy
0.8$0.02flat$3.93 millionN/A0.18Gap Down
SRCH
Searchlight Minerals
0.5$0.02flat$3.44 millionN/A0.00Gap Down
MGHCF
Minco Capital
0.6$0.07flat$3.34 millionN/A-1.40Upcoming Earnings
BAJFF
Camrova Resources
0.0$0.07flat$1.61 millionN/A-3.49Upcoming Earnings
EXPL
Endurance Exploration Group
0.8$0.03flat$1.43 millionN/A0.00
GMOL
General Moly
0.1$0.01flat$1.33 millionN/A-0.01Gap Down
GMOLQ
General Moly
0.1$0.01flat$1.33 millionN/A-0.01Upcoming Earnings
Gap Down
QRMLF
Quest Rare Minerals
0.5$0.02flat$1.30 millionN/A0.00News Coverage
Adamant DRI Processing and Minerals Group logo
ADMG
Adamant DRI Processing and Minerals Group
0.6$0.03flat$409,000.00$50,000.000.00
Blue Gem Enterprise logo
BGEM
Blue Gem Enterprise
0.0$0.00flat$386,000.00N/A0.00
IWMG
I-Wellness Marketing Group
0.0$0.00flat$67,000.00N/A0.00
Modern Cinema Group logo
MOCI
Modern Cinema Group
0.0$0.08flat$0.00N/A0.00
MNVN
Mondial Ventures
0.0$0.00flat$0.00N/A0.00Gap Down
RVNG
Raven Gold
0.0$0.00flat$0.00N/A0.00
RCKE
Rock Energy Resources
0.3$0.00flat$0.00N/A0.00
WCYN
West Canyon Energy
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.